

## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited and ASX	
Name of listed issuer:	Metlifecare Limited
Date this disclosure made:	8 March 2019
Date of last disclosure:	9 June 2016

#### A. Director or senior manager giving disclosure

Full name(s):	Kimmitt Rowland Ellis
Name of listed issuer:	Metlifecare Limited
Name of related body corporate (if applicable):	N/A
Position held in listed issuer:	Director and Chair

#### B. Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Ordinary Shares
Nature of the affected relevant interest(s):	<ol style="list-style-type: none"> <li>1. Beneficial Interest (as a beneficiary of the Ellis Trust) and power to control the disposal and voting of the shares as a co-trustee of the Ellis Trust.</li> <li>2. Director is the husband of Annette Mary Ellis who has a Beneficial Interest (as a beneficiary of the Annette Ellis Trust) and power to control the disposal and voting of the shares as a co-trustee of the Annette Ellis Trust.</li> </ol>
<b>For that relevant interest-</b>	
Number held in class before acquisition or disposal:	<ol style="list-style-type: none"> <li>1. 165,000</li> <li>2. 15,000</li> </ol>
Number held in class after acquisition or disposal:	<ol style="list-style-type: none"> <li>1. 185,000</li> <li>2. 73,100</li> </ol>
Current registered holder(s):	Unknown
Registered holder(s) once transfers are registered:	<ol style="list-style-type: none"> <li>1. Custodial Services Limited.</li> <li>2. Custodial Services Limited.</li> </ol>

**C. Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)**

Type of affected derivative:	N/A
Class of underlying financial products:	N/A
<b>Details of affected derivative-</b>	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative (if any):	N/A
The price specified in the terms of the derivative (if any):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A
<i>For that derivative,-</i>	
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	N/A

**D. Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:	Five.
<b>Details of transactions requiring disclosure-</b>	
Date of transaction:	See attached schedule.
Nature of transaction:	Purchase of shares on-market.
Name of any other party or parties to the transaction (if known):	Unknown.
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	See attached schedule.
Number of financial products to which the transaction related:	See attached schedule.
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	The relevant interests were not acquired during a “closed” period.
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	N/A
Date of the prior written clearance (if any):	N/A

**E. Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:	N/A
Nature of relevant interest:	N/A
<i>For that relevant interest, -</i>	
Number held in class:	N/A
Current registered holder(s):	N/A
<i>For a derivative relevant interest, -</i>	
Type of derivative:	N/A
<b>Details of derivative-</b>	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative (if any):	N/A
The price's specified terms (if any):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A
<i>For that derivative relevant interest, -</i>	
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	N/A

**F. Certification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	8 March 2019
Name and title of authorised person:	Rowena Boereboom, Senior Legal Counsel & Assistant Company Secretary.

## Schedule

<b>1. Ellis Trust</b>			
<b>Date</b>	<b>Price (NZD)</b>	<b>Quantity</b>	<b>Total Consideration (NZD)</b>
5 March 2019	5.1470	10,000	51,470.00
6 March 2019	5.1000	10,000	51,000.00
	<b>Total</b>	<b>20,000</b>	<b>102,470.00</b>

<b>2. Annette Ellis Trust</b>			
<b>Date</b>	<b>Price (NZD)</b>	<b>Quantity</b>	<b>Total Consideration (NZD)</b>
5 March 2019	5.1193	29,000	148,461.09
6 March 2019	5.1000	9,100	46,410.00
6 March 2019	5.1000	20,000	102,000.00
	<b>Total</b>	<b>58,100</b>	<b>296,871.09</b>